IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced that its Board of Directors has elected Yujiro S. Hata as Chairman of the Board, effective June 17, 2026. Hata also serves as President, Chief Executive Officer and director. Terry Rosen, Ph.D., will serve as Lead Independent Director.

IDEAYA is described as a leading precision medicine oncology company with an extensive clinical pipeline and ongoing commercial launch preparations. Hata, who founded IDEAYA over a decade ago, emphasized advancing cancer research and delivering breakthrough therapies for patients with high unmet medical needs.

News Market Reaction – IDYA

+2.26%

+2.26% Session close to close

In the Jun 17 session, IDYA gained 2.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S. Hata, Chairman of the Board. Mr. Hata is currently President and Chief Executive Officer, and a member of IDEAYA's Board. Terry Rosen, Ph.D., will serve as Lead Independent Director of IDEAYA's Board.

"On behalf of the Board of Directors, I would like to congratulate Yujiro on this Chair appointment," said Dr. Terry Rosen, Lead Independent Director, IDEAYA Biosciences. "Since founding IDEAYA over a decade ago, Yujiro's vision, passion for the mission, and leadership have been core to the evolution of IDEAYA from an early science-driven start-up to a leading precision medicine oncology company with an extensive clinical pipeline where commercial launch preparations are underway."

"I am grateful to the board for the opportunity to serve and advance IDEAYA's vision to drive forward our important cancer research and deliver breakthrough therapies for patients to address high unmet medical needs in cancer," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to IDEAYA's vision, strategy, mission, future growth, advancement of its research programs, development and potential commercialization of its product candidates, preparations for potential commercial launches, and the ability to deliver breakthrough therapies to patients with cancer and address unmet medical needs. Such forward-looking statements are based on management's current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA's clinical programs, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials, enrollment rates, safety outcomes, efficacy results, regulatory interactions and decisions, and the ability to translate preclinical findings into clinical benefit, manufacturing and supply risks, competition, changes in standard of care, the timing and success of commercialization efforts, the outcome of collaborations and licensing arrangements, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA's filings with the Securities and Exchange Commission, including IDEAYA's most recent Annual Report on Form 10-K and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-yujiro-s-hata-elected-chairman-of-its-board-of-directors-302802421.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

Who was elected Chairman of IDEAYA Biosciences (NASDAQ: IDYA) on June 17, 2026?

Yujiro S. Hata was elected Chairman of the Board of IDEAYA Biosciences on June 17, 2026. According to IDEAYA, Hata also serves as President, Chief Executive Officer and director, and founded the company over a decade ago.

What role does Terry Rosen hold on the IDEAYA Biosciences (IDYA) board?

Terry Rosen, Ph.D., serves as Lead Independent Director on the IDEAYA Biosciences Board of Directors. According to IDEAYA, Rosen will support board leadership as Yujiro S. Hata assumes the combined role of Chairman, President and Chief Executive Officer.

How might Yujiro S. Hata’s chairmanship affect IDEAYA Biosciences (IDYA) governance?

Yujiro S. Hata now holds the roles of Chairman, President and Chief Executive Officer at IDEAYA Biosciences. According to IDEAYA, this aligns board leadership with the company’s founding vision while Terry Rosen serves as Lead Independent Director to support independent board oversight.

What is IDEAYA Biosciences’ focus as highlighted in the June 17, 2026 IDYA announcement?

IDEAYA Biosciences focuses on precision medicine oncology and developing therapies for cancer patients with high unmet medical needs. According to IDEAYA, it has an extensive clinical pipeline and has begun commercial launch preparations, reflecting its evolution beyond an early science-driven start-up.

What did Yujiro S. Hata say about his new role as IDEAYA (IDYA) Chairman?

Yujiro S. Hata expressed gratitude for the opportunity to serve as Chairman of IDEAYA’s board. According to IDEAYA, he emphasized advancing the company’s vision to drive cancer research and deliver breakthrough therapies addressing high unmet medical needs in cancer.

How long has Yujiro S. Hata been involved with IDEAYA Biosciences (NASDAQ: IDYA)?

Yujiro S. Hata founded IDEAYA Biosciences over a decade ago and has led its evolution since. According to IDEAYA, his leadership helped transform the company from a science-driven start-up into a precision medicine oncology company with an extensive clinical pipeline.